Clinical trial
Research Study in Patients With Severe Ulcerative Colitis
NCT00032305 · Facet Biotech, Industry · Completed
Key facts
| NCT number | NCT00032305 |
|---|---|
| Title | Research Study in Patients With Severe Ulcerative Colitis |
| Official title | A Phase I, Dose-Escalation, Pilot Study of Visilizumab in Patients With Severe Ulcerative Colitis That is Refractory to Corticosteroids |
| Lead sponsor | Facet Biotech, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Ulcerative Colitis |
| Intervention type | Drug |
| Interventions | Visilizumab |
| Enrollment | 20 |
| Start date | Mar 1, 2002 |
| Primary completion | Nov 1, 2005 |
| Completion | Nov 1, 2005 |
| First posted | Mar 18, 2002 |
| Last update posted | Mar 7, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: